<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table id="schedule" class="data" border="0" cellspacing="0" summary="This table shows the date, time, and location of the meeting" cellpadding="2" width="98%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;th id="a2" bgcolor="#cccccc" valign="top" width="35%" align="left" style="height: 19px"&gt;Date&lt;/th&gt;&lt;th id="a3" bgcolor="#cccccc" valign="top" width="30%" align="left" style="height: 19px"&gt;Time&lt;/th&gt;&lt;th id="a4" bgcolor="#cccccc" valign="top" width="45%" align="left" style="height: 19px"&gt;Location&lt;/th&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td valign="top" width="35%" headers="a2" style="height: 64px"&gt;&lt;!-- InstanceBeginEditable name="col2" --&gt;November 12, 2009&lt;br /&gt;November 13, 2009 &lt;!-- InstanceEndEditable --&gt;&lt;/td&gt;&lt;td valign="top" width="30%" headers="a3" style="height: 64px"&gt;&lt;!-- InstanceBeginEditable name="col3" --&gt;8:00 a.m. - 5:00 p.m.&lt;br /&gt;8:00 a.m. - 2:00 p.m. &lt;!-- InstanceEndEditable --&gt;&lt;/td&gt;&lt;td valign="top" width="45%" headers="a4" style="height: 65px"&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="col4" --&gt;The Hilton Hotel&lt;/p&gt;&lt;p&gt;8727 Colesville Road&lt;/p&gt;&lt;p&gt;Silver Spring, M.D. 20910&lt;!-- InstanceEndEditable --&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;h2 class="BlueBar"&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="agenda" --&gt;&lt;/p&gt;&lt;p&gt;On November 12 and 13, 2009, the Committee will discuss strategies and programs designed to communicate with the public about the risks and benefits of FDA-regulated products so as to facilitate optimal use of these products. FDA intends to provide more specific agenda topics no later than 15 days prior to the meeting.&amp;nbsp;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;h2 class="BlueBar"&gt;&lt;a href="[!--$ssLink(&amp;quot;ucm116558.htm&amp;quot;)--]"&gt;Other Meeting Materials&lt;/a&gt;&lt;/h2&gt;&lt;p class="BlueBar"&gt;&amp;nbsp;&lt;/p&gt;&lt;h2 class="BlueBar"&gt;Public Participation Information&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="pubpart" --&gt;&lt;/p&gt;&lt;p&gt;Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.&lt;/p&gt;&lt;ul class="listspace"&gt;&lt;li&gt;Written submissions may be made to the contact person on or before November 4, 2009.&lt;/li&gt;&lt;li&gt;Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on November 12 and between approximately 10:30 a.m. and 11:30 a.m. on November 13, 2009. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 4, 2009.&amp;nbsp;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested person regarding their request to speak by November 5, 2009.&lt;/p&gt;&lt;p&gt;&lt;!-- InstanceEndEditable --&gt;&lt;/p&gt;&lt;h2 class="BlueBar"&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/h2&gt;&lt;p&gt;&lt;!-- InstanceBeginEditable name="contact" --&gt;&lt;/p&gt;&lt;ul class="listspace"&gt;&lt;li&gt;&lt;strong&gt;Lee L. Zwanziger, Designated Federal Official&lt;/strong&gt;&lt;br /&gt;5600 Fishers Lane, Rm 14-90, HFP-1&lt;br /&gt;Rockville, MD 20857&lt;/li&gt;&lt;li&gt;Phone 301-827-2895&lt;/li&gt;&lt;li&gt;FAX: 301-827-4050&lt;br /&gt;e-mail:&amp;nbsp; Lee.Zwanziger@fda.hhs.gov&lt;/li&gt;&lt;li&gt;&lt;strong&gt;FDA Advisory Committee Information Line&lt;/strong&gt;&lt;br /&gt;1-800-741-8138&lt;br /&gt;(301-443-0572 in the Washington, DC, area)&lt;br /&gt;code 8732112560&lt;br /&gt;Please call the Information Line for up-to-date information on this meeting.&lt;br /&gt;&amp;nbsp;&lt;/li&gt;&lt;/ul&gt;&lt;p&gt;FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting.&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Lee L. Zwanziger at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at &amp;nbsp;&lt;a href="/oc/advisory/default.htm"&gt;http://www.fda.gov/AdvisoryCommittees/&lt;/a&gt; for procedures on public conduct during advisory committee meetings.&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).&lt;/p&gt;&lt;p align="center"&gt;&amp;nbsp;&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
